# A Study of AT-101 in Combination With Docetaxel in Squamous Cell Carcinoma Of The Head and Neck

> **NCT01285635** · PHASE2 · TERMINATED · sponsor: **University of Michigan Rogel Cancer Center** · enrollment: 35 (actual)

## Conditions studied

- Squamous Cell Carcinoma of the Head and Neck (SCCHN)

## Interventions

- **DRUG:** AT-101
- **DRUG:** Docetaxel

## Key facts

- **NCT ID:** NCT01285635
- **Lead sponsor:** University of Michigan Rogel Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2010-06
- **Primary completion:** 2012-12
- **Final completion:** 2015-09
- **Target enrollment:** 35 (ACTUAL)
- **Why stopped:** drug is no longer manufactured
- **Last updated:** 2016-03-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01285635

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01285635, "A Study of AT-101 in Combination With Docetaxel in Squamous Cell Carcinoma Of The Head and Neck". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01285635. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*